Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2008 3
2009 4
2010 5
2011 3
2012 21
2013 19
2014 38
2015 59
2016 81
2017 87
2018 121
2019 164
2020 199
2021 35
Text availability
Article attribute
Article type
Publication date

Search Results

743 results
Results by year
Filters applied: . Clear all
Page 1
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM. Keating GM. Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1. Drugs. 2017. PMID: 28213862 Review.
Apremilast (Otezla()) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). ...Enthesitis, dactylitis, physical function and fatigue were also improved with apremilast, and its efficacy was sustained for up to 208 weeks. Apremilast
Apremilast (Otezla()) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). ...Enthesitis, dactylitis, p
Off-label studies on apremilast in dermatology: a review.
Maloney NJ, Zhao J, Tegtmeyer K, Lee EY, Cheng K. Maloney NJ, et al. J Dermatolog Treat. 2020 Mar;31(2):131-140. doi: 10.1080/09546634.2019.1589641. Epub 2019 Apr 2. J Dermatolog Treat. 2020. PMID: 30935262 Free PMC article. Review.
Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studi …
Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. …
Trial of Apremilast for Oral Ulcers in Behcet's Syndrome.
Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Hatemi G, et al. N Engl J Med. 2019 Nov 14;381(20):1918-1928. doi: 10.1056/NEJMoa1816594. N Engl J Med. 2019. PMID: 31722152 Clinical Trial.
BACKGROUND: The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behcet's syndrome. In a phase 2 trial involving patients with Behcet's syndrome, apremilast reduced the incidence and severity of oral ulcers. Data o …
BACKGROUND: The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behcet's syndrom …
The Use of Apremilast in Psoriasis: A Delphi Study.
Carrascosa JM, Belinchón I, Rivera R, Ara M, Bustinduy M, Herranz P. Carrascosa JM, et al. Actas Dermosifiliogr. 2020 Mar;111(2):115-134. doi: 10.1016/j.ad.2019.07.005. Epub 2019 Dec 19. Actas Dermosifiliogr. 2020. PMID: 31864537 Free article. Review. English, Spanish.
BACKGROUND: Experience in the use of apremilast in clinical practice complements the information available from pivotal clinical trials. ...CONCLUSIONS: Apremilast could be a treatment option for patients with a different profile to that of clinical trial participan …
BACKGROUND: Experience in the use of apremilast in clinical practice complements the information available from pivotal clinical tria …
Apremilast (Otezla).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep. Canadian Agency for Drugs and Technologies in Health. 2017. PMID: 30070804 Free Books & Documents. Review.
The objective of this report was to perform a systematic review of the beneficial and harmful effects of apremilast for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy. This is a resubmission based on …
The objective of this report was to perform a systematic review of the beneficial and harmful effects of apremilast for the treatment …
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
Afra TP, Razmi TM, Dogra S. Afra TP, et al. Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12. doi: 10.4103/idoj.IDOJ_437_18. Indian Dermatol Online J. 2019. PMID: 30775293 Free PMC article. Review.
Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014
Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug
Apremilast for Behcet's syndrome--a phase 2, placebo-controlled study.
Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y. Hatemi G, et al. N Engl J Med. 2015 Apr 16;372(16):1510-8. doi: 10.1056/NEJMoa1408684. N Engl J Med. 2015. PMID: 25875256 Free article. Clinical Trial.
Nausea, vomiting, and diarrhea were more common in the apremilast group (with 22, 9, and 12 incidents, respectively, among 55 patients) than in the placebo group (with 10, 1, and 2 incidents, respectively, among 56 patients), findings that were similar to those in previous …
Nausea, vomiting, and diarrhea were more common in the apremilast group (with 22, 9, and 12 incidents, respectively, among 55 patient …
Positioning of apremilast in treatment of Behcet's disease.
Takeno M. Takeno M. Mod Rheumatol. 2020 Mar;30(2):219-224. doi: 10.1080/14397595.2019.1696504. Epub 2019 Dec 2. Mod Rheumatol. 2020. PMID: 31747804 Review.
To suppress inflammatory exacerbations and recurrences which can cause irreversible organ damage, treatment should be individualized according to the disease phenotype and severity. Apremilast, an oral phosphodiesterase 4 inhibitor, is used to treat psoriasis. ...The furth …
To suppress inflammatory exacerbations and recurrences which can cause irreversible organ damage, treatment should be individualized accordi …
[Apremilast].
Quiles Tsimaratos N; Groupe de recherche sur le psoriasis de la Société française de dermatologie. Quiles Tsimaratos N, et al. Ann Dermatol Venereol. 2019 Jun-Jul;146(6-7):470-473. doi: 10.1016/j.annder.2019.04.016. Epub 2019 Jun 19. Ann Dermatol Venereol. 2019. PMID: 31227297 French. No abstract available.
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R. Schafer PH, et al. Cell Signal. 2014 Sep;26(9):2016-29. doi: 10.1016/j.cellsig.2014.05.014. Epub 2014 May 29. Cell Signal. 2014. PMID: 24882690 Free article.
Apremilast did not significantly inhibit other PDEs, kinases, enzymes, or receptors. While both apremilast and thalidomide share a phthalimide ring structure, apremilast lacks the glutarimide ring and thus fails to bind to cereblon, the target of thalidomide
Apremilast did not significantly inhibit other PDEs, kinases, enzymes, or receptors. While both apremilast and thalidomide sha
743 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page